Table of Contents

• 1.   Market Introduction
  •   1. Objectives of the Study
      2. Market Definition
      3. Market Scope
       3.1 . Years Considered for the Study
       3.2 . Market Covered
      4. Currency
      5. Limitations
      6. Stakeholders
    
• 2.   Research Applicationology
  •   1. Research Data
       1.1 . Secondary Data
        1.1.1 . Key Data from Secondary Sources
       1.2 . Primary Data
        1.2.1. Key Data from Primary Sources
      2. Market Size Estimation
      3. Market Breakdown and Data Triangulation
      4. Assumptions for the Study
    
• 3.   Executive Summary
  •   1. Market Outlook
      2. Segment Outlook
      3. Competitive Insights
    
• 4.   Drug and Gene Delivery Systems Market Variables, Trends and Scope

  •   1. Market Lineage Outlook
      2. Penetration and Growth Prospect Mapping
      3. Industry Value Chain Analysis
      4. Cost Analysis Breakdown
      5. Technology Overview
      6. Regulatory Framework
       6.1. Reimbursement Framework
       6.2. Standards and Compliances

• 5.   Market Overview
  •   1. Market Dynamics
       1.1. Market Driver Analysis
        1.1.1. Increasing focus of Drug and Gene Delivery Systems Companies on Brand Protection
        1.1.2. Untapped Opportunities in Emerging Regions
       1.2. Market Restraint Analysis
        1.2.1. High Cost Associated with Implementation of Predictive Analysis
       1.3. Industry Challenges
        1.3.1. Presence of Ambiguous Regulatory Framework
    
• 6.   Drug and Gene Delivery Systems Market Analysis Tools
  •   1. Industry Analysis - Porter’s
       1.1. Supplier Power
       1.2. Buyer Power
       1.3. Substitution Threat
       1.4. Threat from New Entrants
       1.5. Competitive Rivalry
      2. Pestel Analysis
       2.1. Political Landscape
       2.2. Environmental Landscape
       2.3. Social Landscape
       2.4. Technology Landscape
       2.5. Legal Landscape
      3. Major Deals And Strategic Alliances Analysis
       3.1. Joint Ventures
       3.2. Mergers and Acquisitions
       3.3. Licensing and Partnership
       3.4. Technology Collaborations
       3.5. Strategic Divestments
      4. Market Entry Strategies
      5. Case Studies
    
• 7.   Drug and Gene Delivery Systems Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Oral
      2. Inhalation
      3. Transdermal
      4. Injectable
      5. Ocular
      6. Nasal
      7. Topical

• 8.   Drug and Gene Delivery Systems Market, By Delivery System Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Drug Delivery Systems
       1.1. Intrauterine Implants
       1.2. Prodrug Implants
       1.3. Polymeric Drug Delivery
       1.4. Targeted Drug Delivery
      2. Gene Delivery Systems
       2.1. Viral Gene Delivery
        2.1.1. Adenovirus Vector
        2.1.2. Lentivirus Vector
        2.1.3. Retrovirus Vector
        2.1.4. Adeno-associated Virus Vector
        2.1.5. Sendai Virus Vector
        2.1.6. Herpes Simplex Virus Vector
        2.1.7. Others
       2.2. Non-viral Gene Delivery
        2.2.1. Natural Organic Compounds
        2.2.2. Physical Methods
        2.2.3. Chemical Methods
       2.3. Combined Hybrid System

• 9.   Drug and Gene Delivery Systems Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Infectious Diseases
      2. Oncology
      3. Ophthalmology
      4. Urology
      5. Diabetes
      6. CNS
      7. Others

• 10.   North America Drug and Gene Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. U.S.A
       2.2. Canada
       2.3. Mexico
      3. Market Size (USD Million) Forecast for North America 2023-2031

• 11.   Latin America Drug and Gene Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. Brazil
       2.2. Venezuela
       2.3. Argentina
       2.4. Rest of Latin America
      3. Market Size (USD Million) Forecast for Latin America 2023-2031

• 12.   Europe Drug and Gene Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. Germany
       2.2. U.K
       2.3. France
       2.4. Italy
       2.5. Spain
       2.6. Russia
       2.7. Poland
       2.8. Rest of Europe
      3. Market Size (USD Million) Forecast for Europe 2023-2031

• 13.   Asia Pacific Drug and Gene Delivery Systems Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. Japan
       2.2. China
       2.3. India
       2.4. Australia and New Zealand
       2.5. ASEAN
       2.6. Rest of Asia Pacific
      3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

• 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. GCC
       2.2. Israel
       2.3. South Africa
       2.4. Rest of MEA
      3. Market Size (USD Million) Forecast for MEA 2023-2031

• 15.   Market Share Analysis and Competitive Landscape
  •   1. Global Landscape - Key Players, Revenue and Presence
      2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
      3. Global Emerging Companies
      4. North America - Market Share Analysis and Key Regional Players
      5. Europe - Market Share Analysis and Key Regional Players
      6. Asia Pacific - Market Share Analysis and Key Regional Players
      7. Global Key Player - Growth Matrix
    
• 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Route of Administrations Offered and Financial Layouts)

  •   1. Pfizer, Inc
       1.1. Company Overview
       1.2. Route of Administration Portfolio
       1.3. SWOT Analysis
       1.4. Financial Overview
       1.5. Strategic Overview
      2. F. Hoffmann-La Roche Ltd
       2.1. Company Overview
       2.2. Route of Administration Portfolio
       2.3. SWOT Analysis
       2.4. Financial Overview
       2.5. Strategic Overview
      3. Johnson and Johnson Private Ltd
       3.1. Company Overview
       3.2. Route of Administration Portfolio
       3.3. SWOT Analysis
       3.4. Financial Overview
       3.5. Strategic Overview
      4. Novartis AG
       4.1. Company Overview
       4.2. Route of Administration Portfolio
       4.3. SWOT Analysis
       4.4. Financial Overview
       4.5. Strategic Overview
      5. Bayer AG
       5.1. Company Overview
       5.2. Route of Administration Portfolio
       5.3. SWOT Analysis
       5.4. Financial Overview
       5.5. Strategic Overview
      6. Becton, Dickinson and Company
       6.1. Company Overview
       6.2. Route of Administration Portfolio
       6.3. SWOT Analysis
       6.4. Financial Overview
       6.5. Strategic Overview
      7. Uniqure N.V
       7.1. Company Overview
       7.2. Route of Administration Portfolio
       7.3. SWOT Analysis
       7.4. Financial Overview
       7.5. Strategic Overview
      8. SiBiono GeneTech Co
       8.1. Company Overview
       8.2. Route of Administration Portfolio
       8.3. SWOT Analysis
       8.4. Financial Overview
       8.5. Strategic Overview
      9. Shanghai Sunway Biotech Co., Ltd
       9.1. Company Overview
       9.2. Route of Administration Portfolio
       9.3. SWOT Analysis
       9.4. Financial Overview
       9.5. Strategic Overview
      10. Human Stem Cells Institute
       10.1. Company Overview
       10.2. Route of Administration Portfolio
       10.3. SWOT Analysis
       10.4. Financial Overview
       10.5. Strategic Overview
      11. Amgen
       11.1. Company Overview
       11.2. Route of Administration Portfolio
       11.3. SWOT Analysis
       11.4. Financial Overview
       11.5. Strategic Overview
      12. Oxford BioMedica
       12.1. Company Overview
       12.2. Route of Administration Portfolio
       12.3. SWOT Analysis
       12.4. Financial Overview
       12.5. Strategic Overview
      13. Roche
       13.1. Company Overview
       13.2. Route of Administration Portfolio
       13.3. SWOT Analysis
       13.4. Financial Overview
       13.5. Strategic Overview
      14. AstraZeneca
       14.1. Company Overview
       14.2. Route of Administration Portfolio
       14.3. SWOT Analysis
       14.4. Financial Overview
       14.5. Strategic Overview
      15. Epeius Biotechnologies
       15.1. Company Overview
       15.2. Route of Administration Portfolio
       15.3. SWOT Analysis
       15.4. Financial Overview
       15.5. Strategic Overview

• 17.   Pre and Post COVID-19 Impact

  •   1. Positive influence on the healthcare industry
      2. The financial disruption of the manufacturing sector
      3. Impact of COVID-19 on emerging companies
      4. Significant mandates in the healthcare regulations initiated by
                administrations
      5. The overall economic slowdown of the developing and developed nations

• 18.   FutureWise SME Key Takeaway Points for Client